Celularity Inc. (CELU)
CELU trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.42
-3.40% on the day
Market cap
$46.1M
Nano cap
Revenue · 2025
$26.6M
-51.0% on 2024
Net income · 2025
-$91.7M
-345.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | CELU on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001752828 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $26.6M |
| Net income | -$91.7M |
| Operating income | -$61.3M |
| Net margin | -345.4% |
| Operating margin | -230.9% |
| Revenue growth | -51.0% |
| Cash | $6.2M |
| Total assets | $107.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.7× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-01-08 |
| Latest annual report | 10-K | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-09-29 |
| Latest current report | 8-K | 2026-09-29 |
| Latest proxy | DEFA14A | 2025-11-07 |
Source: SEC EDGAR submissions feed, 556 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SER | Serina Therapeutics Inc. | $1.82 | -6.19% | $46.2M |
| ANVS | Annovis Bio Inc. | $1.06 | -7.83% | $45.2M |
| ACET | Adicet Bio Inc. | $5.11 | -7.59% | $47.8M |
| ELTX | Elicio Therapeutics Inc. | $1.77 | -5.85% | $48.0M |
| DWTX | Dogwood Therapeutics Inc. | $1.30 | -5.11% | $44.2M |
| HOWL | Werewolf Therapeutics Inc. | $0.9911 | +0.95% | $48.2M |
| CLNN | Clene Inc. | $3.39 | -7.88% | $48.2M |
| IBIO | iBio Inc. | $0.7818 | -13.44% | $50.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier